Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Fennec Pharmaceuticals Inc. (T.FRX) had Stock-Based Compensation of 6.21M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
-0.88M |
|
-- |
|
-- |
|
-- |
|
-0.26M |
|
-- |
|
-0.88M |
|
-0.88M |
|
-0.88M |
|
-0.88M |
|
-0.88M |
|
-0.88M |
|
-0.26M |
|
-0.24M |
|
27.89M |
|
27.89M |
|
-0.03 |
|
-0.03 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
67.86M |
|
-- |
|
-- |
|
-- |
|
74.05M |
|
-6.19M |
|
-6.19M |
|
-6.19M |
|
28.06M |
|
| Cash Flow Statement Financials | |
-8.97M |
|
-- |
|
2.51M |
|
36.69M |
|
30.23M |
|
-6.46M |
|
|
Stock-Based Compensation |
6.21M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.69 |
|
-- |
|
-- |
|
1.33 |
|
-4.03 |
|
94.70% |
|
-1.52% |
|
-1.52% |
|
-- |
|
-5.12% |
|
-5.12% |
|
-8.97M |
|
-- |
|
-- |
|
-- |
|
0.25 |
|
0.27 |
|
0.64 |
|
139.69 |
|
14.20% |
|
14.20% |
|
-1.30% |
|
-4.69% |
|
-0.22 |
|
-0.32 |
|
-0.32 |
|